| Market Capitalization (Millions $) |
2,089 |
| Shares
Outstanding (Millions) |
142 |
| Employees |
88 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-60 |
| Cash Flow (TTM) (Millions $) |
-36 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Silence Therapeutics Plc is a biotechnology company focused on developing and commercializing novel therapies using RNA interference (RNAi) technology. RNAi is a naturally occurring process that regulates gene expression, and Silence works to harness this mechanism to silence or selectively modulate the expression of disease-causing genes.
The company's proprietary platform, AtuRNAi, enables the development of targeted therapeutics for various indications, including cancer, genetic disorders, and cardiovascular diseases. Silence Therapeutics utilizes its expertise in small interfering RNA (siRNA) molecules and lipid nanoparticle delivery systems to develop safe and effective treatments.
Silence Therapeutics has a strong portfolio of product candidates and a robust pipeline of potential therapies at various stages of development. The company collaborates with various partners, including pharmaceutical and biotechnology companies, to leverage their expertise and resources in advancing its development programs.
Overall, Silence Therapeutics aims to revolutionize the treatment of diseases by utilizing the power of RNAi to silence the genes responsible for causing various medical conditions.
Company Address: 12 Hammersmith Grove London 0
Company Phone Number: 3457 6900 Stock Exchange / Ticker: NASDAQ SLN
|
